Novo Nordisk suffers dual semaglutide patent setbacks in Europe
By Melissa Ritti ( October 26, 2026, 20:23 GMT | Insight) -- Novo Nordisk has lost a European semaglutide patent with the European Patent Office's Board of Appeal in a decision published Monday rejecting the Wegovy and Ozempic-maker's eleventh-hour effort to amend its claims. In a separate dispute with Sandoz, the Unified Patent Court last week said its judges can stop patent owners from abandoning rights to avoid adverse validity determinations.The Unified Patent Court can prevent patent owners from using withdrawals to frustrate validity challenges, its Milan Central Division ruled last week in a dispute between Sandoz and Novo Nordisk....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.